
News|Articles|January 1, 2006
First-time generic approvals
Hydromorphone tablets 2, 4, and 8 mg (equiv to Dilaudid tablets)
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
COVID-19 vaccines could help tumors respond better to immune checkpoint inhibitors
2
Researchers highlight DR-70 as a possible biomarker for early bladder cancer detection
3
Gilead’s Single-Tablet HIV Regimen Meets Primary Endpoints
4
FDA approves Poherdy, first biosimilar of Perjeta, to treat HER-positive breast cancer
5


















































